The sodium-dependent organic anion transporter SOAT specifically transports sulfated steroid hormones and is supposed to play a role in testicular steroid regulation and male fertility. The present study aimed to identify novel specific SOAT inhibitors for further in vitro and in vivo studies on SOAT function. More than 100 compounds of different molecular structures were screened for inhibition of the SOATmediated transport of dehydroepiandrosterone sulfate in stably transfected SOAT-HEK293 cells. Twenty-five of these with IC 50 values covering four orders of magnitude were selected as training set for 3D pharmacophore modelling. The SOAT pharmacophore features were calculated by CATALYST and consist of three hydrophobic sites and two hydrogen bond acceptors. By substrate database screening, compound T 0511-1698 was predicted as a novel SOAT inhibitor with an IC 50 of 15 mM. This value was confirmed by cell-based transport assays. Therefore, the developed SOAT pharmacophore model demonstrated its suitability in predicting novel SOAT inhibitors.
Introduction
Sulfated steroid hormones, such as dehydroepiandrosterone sulfate (DHEAS) or estrone-3-sulfate, are usually considered to be biologically inactive metabolites as they cannot activate classical steroid receptors (Strott, 2002) . They are present in the blood circulation at quite high concentrations, but generally exhibit low membrane permeation due to their physicochemical properties (Mueller et al., 2015) . However, sulfo-conjugated steroid hormones can actively be imported into specific target cells via uptake carriers and, after hydrolysis by the steroid sulfatase (StS) (so-called sulfatase pathway), contribute to the overall steroid regulation (Reed et al., 2005; Pasqualini and Chetrite, 2012; Labrie, 2015) . In 2004 we identified a novel uptake carrier, named sodium-dependent organic anion transporter SOAT, which specifically transports sulfated steroid hormones, such as DHEAS, estrone-3-sulfate, bestradiol-3-sulfate, pregnenolone sulfate, and androstenediol-3-sulfate in a sodium-dependent manner (Geyer et al., 2004) . In rat and mouse, Soat showed a broader tissue expression, including skin, testis and lung (Geyer et al., 2004; Grosser et al., 2013) , while in humans SOAT is predominantly expressed in the testis with lower expression in the placenta and breast tissue (Geyer et al., 2007) . In the testis, SOAT/Soat was localised to spermatocytes and round spermatids and, therefore, this carrier is supposed to play a role in testicular steroid regulation and male fertility Grosser et al., 2013) . More recently, SOAT expression was also demonstrated in breast cancer tissue (unpublished data). Here, SOAT may contribute to the hormone-dependent proliferation due to the import of estrone-3-sulfate and even DHEAS, making SOAT a potential drug target for anti-proliferative therapy.
SOAT (gene symbol SLC10A6) phylogenetically belongs to the solute carrier family SLC10, which overall consists of seven members (SLC10A1eSLC10A7). The founding members of this carrier family, the hepatic Na þ /taurocholate co-transporting polypeptide NTCP (SLC10A1) and the intestinal apical sodium-dependent bile acid transporter ASBT (SLC10A2) are important factors for the maintenance of the enterohepatic circulation of bile acids between the liver and the gut D€ oring et al., 2012) . Furthermore, ASBT is of particular interest in several pharmacological aspects. Regarding molecular drug design, ASBT-mediated uptake from the gut is used to improve the oral bioavailability of drugs by coupling them with bile acids (Kramer et al., 1994; Kramer, 2011) . Furthermore, ASBT is a drug target for cholesterol-lowering therapy, because inhibition of bile acid reuptake in the gut stimulates de novo bile acid synthesis from cholesterol in the liver (Kramer and Glombik, 2006) .
In the present study, we searched for novel SOAT inhibitors for further in vitro and in vivo studies in order to clarify the role of SOAT in testicular steroid regulation and for proliferation of hormonedependent breast cancer cells. Therefore, we analysed the SOAT inhibitory pattern in detail with a set of more than 100 different compounds and established a 3D pharmacophore model for the identification of further inhibitors of SOAT. Because of the very high amino acid sequence identity of SOAT and ASBT, we also compared the SOAT pharmacophore model with the already established pharmacophore model of rabbit Asbt (Baringhaus et al., 1999) in order to determine the potential cross-inhibition between both carriers. Such a cross-inhibition after oral application of an SOAT inhibitor would be of pharmacological relevance as ASBT inhibition would hamper the enterohepatic circulation of bile acids.
Material and methods

Chemicals and radiochemicals
All chemicals, unless otherwise stated, were from SigmaeAldrich. Zeocin and hygromycin were purchased from Invitrogen. Materials used for cultivation of HEK293 cells were purchased from Gibco and SigmaeAldrich. 
Cloning and establishment of cell lines
Cloning of human SOAT and establishment of a stably transfected SOAT-HEK293 cell line was reported previously (Geyer et al., 2007) . Briefly, the full-length SOAT cDNA was cloned into the Flp-In pcDNA5/FRT/TO expression vector carrying a Flp recombinase target site (FRT) and a hygromycin resistance gene (Invitrogen). In this vector, SOAT expression is under the control of the cytomegalovirus promoter and a tetracycline operator sequence. The SOAT-HEK293 cell line was established using the Flp-In expression system and the commercially available Flp-In T-Rex 293 host cell line (Invitrogen) with stable expression of the tetracycline repressor. In the absence of tetracycline, the tetracycline repressor effectively binds to the tetracycline operator sequence and blocks SOAT transcription from the cytomegalovirus promoter. In the same way, a stably transfected ASBT-HEK293 cell line was established with the human ASBT cDNA sequence according to GenBank accession number NM_000452.
Inhibition studies in SOAT-HEK293 and ASBT-HEK293 cells
For inhibition studies, 24-well plates were coated with poly-Dlysine for better attachment of the cells. Cells (1.25 Â 10 5 per well)
were plated and grown in standard medium for 72 h. SOAT and ASBT expression was induced by pre-incubation with tetracycline
(1 mg/ml). SOAT (Geyer et al., 2007) , this longer uptake phase was required to ensure adequate uptake ratios for subsequent IC 50 determinations. However, comparative uptake experiments with 1 min or 5 min uptake phase revealed identical IC 50 values for selected compounds (data not shown). The transport phase was terminated by removing the transport buffer and washing the cells five times with ice-cold PBS. Cell-associated radioactivity and protein contents were determined as described previously (Geyer et al., 2007) . For calculation of the IC 50 values, the negative control (uptake in not carrier expressing HEK293 cells) was set to 0% and the respective positive control (uptake in carrier expressing HEK293 cells without inhibitor) was set to 100%.
Generation of the 3D QSAR model
The 3D quantitative structure-activity relationship (QSAR) model was generated using the CATALYST software (version 2.11, Accelrys). All molecules of the training set were built in CATALYST and transformed into 3D structures followed by a local minimisation using the CHARMM-like force. Subsequent conformational analysis within a 20 kcal/mol energy window ("best searching procedure") yielded a diverse and representative set of up to 250 conformations per molecule (Smellie et al., 1995) . CATALYST uses molecular structures as templates consisting of chemical functions positioned in space. It is assumed that the most relevant biological features bind effectively with complementary functions on the respective binding protein. The model generation in CATALYST (CatHypo module) starts with the selection of the most relevant biological features from the most active compounds of the training set (Sprague and Hoffmann, 1997) . CATALYST then evaluates all generated models against all compounds of the training set covering a broad range of activity. Only models that best explain the entire structure-activity relationship in the training set are finally reported. This statistical relevance takes into account the cost of each model relative to the null hypothesis as well as the correlation coefficients. CATALYST pharmacophores are described by a set of hydrophobic, hydrogen bond donor and acceptor functions, as well as positively and negatively ionisable features distributed within 3D space. The hydrogen bonding features are vectors, while all other functions are points.
Results
Initial screening
Although SOAT has no general transport activity for bile acids, several bile acids were quite good SOAT inhibitors in previous experiments (Geyer et al., 2007) . For more systematic analysis of the inhibitory pattern of SOAT, a series of physiologically occurring bile acids was used to obtain IC 50 values by inhibition of [ 3 H]DHEAS transport of stably transfected SOAT-HEK293 cells. Table 1 shows the structures of the bile acids used with the corresponding IC 50 values, which cover about four orders of magnitude (0.5 mMe972 mM). Direct comparison of lithocholic acid and taurolithocholic acid with their corresponding sulfated forms revealed 2-to 6-fold higher inhibitory potency with the sulfate group at position 3 (R 1 ). The secondary bile acids, hyocholic acid and hyodeoxycholic acid, are characterised by additional hydroxyl groups at position 6 (R 2 ), which decreased the inhibitory potency compared to chenodeoxycholic acid and lithocholic acid by 17-and 87-fold, respectively. Among all bile acids tested, hyocholic acid with its four hydroxyl groups was identified as the least potent inhibitor of SOAT (IC 50 ¼ 971.8 mM). At position 7 (R 3 ), the following inhibitory pattern was found, starting with the most potent compounds: H (lithocholic acid) z 7a-OH (chenodeoxycholic acid) > ¼O (7-ketolithocholic acid) > 7b-OH (ursodeoxycholic acid). Furthermore, the presence of a hydroxyl group at position 12 (R 4 ) significantly reduced the inhibitory potency of the bile acid (e.g. chenodeoxycholic acid vs. cholic acid). In contrast, substitutions of the bile acids at R 5 with glycine showed no general trend for better 
or lower inhibition, while substitution with taurine at that position revealed a distinct improvement of inhibition, in particular, for tauroursodeoxycholic acid and taurolithocholic acid 3-sulfate, but not for taurochenodeoxycholic acid. In summary, 3a-monohydroxy bile acids and bile acids with a sulfate group at position 3 are the most potent inhibitors of SOAT from the group of bile acids. However, it has to be noted that taurolithocholic acid 3-sulfate is not only a potent inhibitor, but also a week substrate of SOAT (Geyer et al., 2007) . Bile acids normally have a typical cis-trans-trans conformation of the A, B and C rings of the steroid nucleus. In contrast, sulfoconjugated steroid hormones, which are substrates of SOAT, are characterised by a trans-trans-trans conformation of the rings. Consequently, we additionally determined the IC 50 values of a set of trans-trans-trans steroid hormones ( Table 2) . Most of these compounds did not inhibit SOAT when they were not sulfo-conjugated. In contrast, the sulfo-conjugated forms e estrone-3-sulfate and pregnenolone-3-sulfate e showed strong inhibition of the DHEAS transport by SOAT. Both compounds have previously been identified as substrates of SOAT (Geyer et al., 2007) . Therefore, the inhibitory effect of these compounds can be regarded as a competition with another transported substrate (DHEAS). In the case of b-estradiol-3,17-disulfate and corticosterone-21-sulfate it is currently unknown if these compounds are also transported by SOAT or not. Interestingly, whereas cortisol with a hydroxyl group at position 11 did not show any inhibition of SOAT, cortisone with a ketone group at the same position revealed pronounced inhibitory potency, indicating that the oxidation status at the C 11 position is of significant relevance for SOAT inhibition. Finally, digitonin, a steroid glycoside from digitalis purpurea with a cis-trans-cis conformation of the steroid rings, was a powerful inhibitor of SOAT.
3D QSAR pharmacophore model of SOAT
Apart from bile acids and steroid hormones, many further compounds were tested as potential inhibitors of SOAT. For development of the pharmacophore model, 25 of these compounds were selected and used as a training set. These included structurally similar compounds with different IC 50 values, as well as structurally divergent compounds with similar IC 50 values. Overall, the IC 50 values covered four orders of magnitude (IC 50 ¼ 0.15 mMe1000 mM) (Table 3) . Fig. 1 illustrates some of the training set compounds. Additional structural information for the used bile acids is given in Table 1 , and compounds previously used as the training set for the Asbt pharmacophore (Baringhaus et al., 1999) are given in Fig. 2 . The best hypothesis for the calculated SOAT pharmacophore model, proposed by CATALYST, is illustrated in Fig. 3 and consists of three hydrophobic sites (blue spheres) and two hydrogen bond acceptors (two green spheres, with the smaller sphere giving the origin and the larger sphere giving the direction of the hydrogen bond). Fig. 4 depicts the correlation between the experimentally measured IC 50 values versus the predicted activities of the training set compounds, whereby the measured IC 50 values of >1000 were set to 10.000. The correlation coefficient was at r ¼ 0.89 ± 0.32, demonstrating good predictive ability of this SOAT pharmacophore model.
For example, the best inhibitory bile acid TLCS (IC 50 ¼ 0.5 mM) maps all five features of the pharmacophore model as follows (Fig. 3A) : the hydrophobic features cover the methyl groups at positions 18 and 21, as well as the A-ring of the steroid nucleus, and the sulfate group at position 3, as well as the sulfonyl group of the taurine residue, act as hydrogen bond acceptors. In contrast, the less potent inhibitors bromosulfophthalein (BSP) (IC 50 ¼ 3.6 mM) and S 1647 (IC 50 ¼ 1.1 mM) only matched four of the five pharmacophore features ( Fig. 3B and C, respectively). While BSP does not cover one of the hydrogen bond acceptor groups (Fig. 3B) , S 1647 lacks mapping of a hydrophobic site (Fig. 3C) .
In order to identify novel SOAT inhibitors, the Sanofi-Aventis database of commercially available molecules (~12 million molecules) was screened for compounds matching the pharmacophore and revealed 67,360 hits. After applying a >50% fitting value, 3437 virtual hits remained. This number was decreased by a shape query of TLCS to 180 hits. A shape restriction to S 1647 limited the number of hits to 75 compounds and an intersection of both (TLCS and S 1647) shape queries limited the number of hits to four compounds. For the shape query of BSP, no compound was found. From these hits, compounds with particularly low estimated IC 50 values were selected for validation of the SOAT pharmacophore model and were used for experimental determination of the IC 50 values.
Whereas, T 5239532 (IC 50 ¼ 137 mM), T 5573915 (IC 50 ¼ 57 mM) and T 5854015 (IC 50 ¼ 9 mM) showed higher than predicted IC 50 values (being 0.83 mM, 1.43 mM, and 1.28 mM, respectively), the predicted and measured IC 50 values were identical for compound T 0511-1698, being 15 mM (Table 4 , Fig. 5) . Therefore, the 3D pharmacophore model was suitable in predicting novel SOAT inhibitors of completely different chemical structures compared to the compounds of the training set. Closer analysis revealed that only four of five features of the SOAT pharmacophore are mapped by compound T 0511-1698, and one of the hydrogen bond acceptors is not covered (Fig. 5B) , which might explain the lower inhibitory power of T 0511-1698 compared with TLCS, which mapped all five pharmacophore features. Furthermore, all compounds were additionally tested for potential cross-inhibition of ASBT. Only compound T 0511-1698 showed weak interaction with ASBT with IC 50 of 350 mM (Table 4) .
Comparison of the SOAT and ASBT pharmacophore models
Because of the high sequence identity between SOAT and ASBT, we were interested to determine whether the 3D pharmacophore models of these carriers might overlap. Therefore, we tested 14 compounds that were used as the training set of the previously published Asbt pharmacophore (Baringhaus et al., 1999) (Fig. 2) for SOAT inhibition and compared the measured IC 50 values (Table 5 , Fig. 6 ). Direct comparison of these data indicated no significant Fig. 6 ). However, certain compounds were good inhibitors for both carriers, such as S 3720 (IC 50 ¼ 8 mM for Asbt and 1.1 mM for SOAT) and S 1647 (IC 50 ¼ 4 mM for Asbt and 1 mM for SOAT), which allows us to suggest that both pharmacophore models might share some common domains. Both pharmacophore models have three hydrophobic features, but differ in their hydrogen bond donor/ acceptor features. Interestingly, fitting of compound S 3720 into both pharmacophore models showed mapping for all three hydrophobic features by the identical structural domains (chloro group, benzyl group, and phenyl group) of S 3720 (Fig. 7) . However, one hydrogen bond acceptor of the SOAT pharmacophore fits to the ketone group of the 2-thioxo-pyrimidin-4,6-dion ring of S 3720, whereas the thioketo group of the same ring maps the hydrogen bond acceptor of the Asbt pharmacophore. The other hydrogen bond acceptor of the SOAT pharmacophore, as well as the hydrogen bond donor of the Asbt pharmacophore, remains unfilled. From this direct comparison of the pharmacophore mapping of S 3720, it can be concluded that both pharmacophore models overlap in their hydrophobic features, but significantly differ in the orientation of their hydrogen bond donor/acceptor groups.
Discussion
In 2004, SOAT was identified as a novel member of the SLC10 carrier family, which includes the bile acid transporters NTCP and Fig. 1 . Chemical structures of the molecules that were included in the training set (Table 3) for generation of the SOAT pharmacophore model. Fig. 2 . Chemical structures of the molecules that were used as the training set for generation of the Asbt pharmacophore model by Baringhaus et al. (1999) and that were also experimentally tested for SOAT inhibition in the present study (Table 5). ASBT (Geyer et al., 2004 . SOAT specifically transports sulfated steroid hormones, including DHEAS, 16a-hydroxy-DHEAS, androstenediol-3-sulfate, estrone-3-sulfate, b-estradiol-3-sulfate, and pregnenolone sulfate in a strictly sodium-dependent manner (Geyer et al., 2007; Fietz et al., 2013; Galuska et al., 2013; Schweigmann et al., 2014) . Sulfated steroid hormones are present in the plasma at much higher concentrations than the corresponding free steroid forms, and are considered as a reservoir for the synthesis of free steroid hormones, which have potent regulatory functions (Labrie, 2015) . While lipophilic free steroid hormones are able to pass the cell membrane by diffusion, the negatively charged steroid sulfates can access the intracellular compartment only by carrier-mediated import via SOAT or other uptake carriers (Geyer et al., 2007; Mueller et al., 2015) . After cleavage of the sulfate group by the steroid sulfatase these imported steroid sulfates can participate in the steroid regulation at nuclear estrogen and androgen receptors (Reed et al., 2005; Pasqualini and Chetrite, 2012) . SOAT is highly expressed in germ cells of the human testis and is supposed to play a role in testicular steroid regulation and male fertility by importing sulfated steroid hormones Grosser et al., 2013) . Furthermore, SOAT was localised in hormone-dependent breast cancer tissue (unpublished data) and here might be of pathophysiological relevance due to steroid sulfate import. In the present study, we aimed to develop a common feature-based 3D pharmacophore model for SOAT in order to identify novel and specific SOAT inhibitors for further in vivo and in vitro studies in both fields.
Despite the high phylogenetic relationship to ASBT, SOAT is transport-negative for the bile acids taurocholic acid, cholic acid, chenodeoxycholic acid and deoxycholic acid (Geyer et al., 2007) . However, several bile acids are quite good inhibitors of SOAT, even in the low micro molar range. Bile acids have certain structural similarities to steroid hormones, but with one major difference: whereas the A/B rings of the steroid nucleus are trans orientated in the steroid hormones, they have a cis orientation in the bile acid molecules, and this might discriminate between steroid-like SOAT substrates and inhibitors (Geyer et al., 2007; D€ oring et al., 2012) . Interestingly, further hydroxyl groups at positions 7 and/or 12 of the bile acid molecule, which are not present in steroid hormones, significantly decreased the inhibitory power of the respective bile The three hydrophobic sites (light blue) of BSP fit to the model, as well as one hydrogen bond acceptor (green), but the second hydrogen bond acceptor remains free. (C) Both hydrogen bond acceptors (green) and two hydrophobic sites (light blue) fit to compound S 1647, but one hydrophobic site is not covered. The spheres used for shape restriction of BSP and S 1647 are additionally indicated in grey. acid, indicating that a non-substituted steroid nucleus might be one of the possible core structures that are required for binding to SOAT. However, as a steroid compound generally has the potential for cross-inhibition of ASBT, it is not regarded as a promising core structure for the development of novel specific SOAT inhibitors.
Apart from bile acids, further non-steroidal SOAT inhibitors have been identified, including the toxins 1-(u-sulfooxyethyl)pyrene and 2-sulfooxymethylpyrene and the hormone L-thyroxine, as well as the hepatodiagnostic dye and NTCP substrate BSP. Furthermore, the propanolamine compounds S9087, S8214, S9202 and S9203, as well as the barbiturate compound S3740, showed significant inhibition of the SOAT transport with IC 50 < 50 mM. The latter compounds were previously used as training-set compounds for Fig. 2 and listed in Table 5 between Asbt and SOAT. The values for Asbt were reported before by Baringhaus et al. (1999) and the values for SOAT were experimentally determined in the present study.
generation of the Asbt pharmacophore model (Baringhaus et al., 1999) and all showed significant inhibition of the Asbt, which might be explained by partial overlap of the two pharmacophore models for Asbt and SOAT. Therefore, a specific and non-toxic SOAT inhibitor could not be established so far. However, based on the SOAT pharmacophore model developed in the present study, several new molecules of different chemical structures (Fig. 5A ) were identified that all showed low or even no cross-inhibition with ASBT. Based on these structures, more potent SOAT inhibitors can now be developed. However, it has to be stated that the SOAT pharmacophore model also has some limitations, as the inhibitory power prediction did not fit with the experimentally measured IC 50 values for all compounds analysed. Furthermore, there are some discrepancies between the fitting status into the pharmacophore model and the inhibitory power of certain compounds. For example, BSP as well as compound T 0511-1698 both map only four of the five features of the SOAT pharmacophore, whereas the real IC 50 value was correctly predicted for T 0511-1698, but not for BSP. This might indicate that further features could be relevant for SOAT inhibition which are not covered by the SOAT pharmacophore model.
The present study only analysed cross-inhibition of the SOAT inhibitors with ASBT, as the phylogenetically most related carrier to SOAT. But it has to be noted that apart from SOAT further carriers from the Organic Anion Transporter (OAT) family and from the Organic Anion Transporting Polypeptide (OATP) family as well as NTCP are able to transport sulfated steroid hormones , and could also show cross-inhibition with SOAT inhibitors. These carriers are largely expressed in the liver and kidney. So, inhibition of these carriers could reduce the overall hepatobiliary and renal excretion of steroid sulfates. As these carriers play also an important role for the excretion of many drugs, relevant drug-drug-interactions cannot be excluded for novel SOAT inhibitors.
In conclusion, we were able to develop a 3D pharmacophore model for SOAT with three hydrophobic sites and two hydrogen bond acceptors. The bile acid with the highest inhibitory power, TLCS, mapped all five features. SOAT inhibition by compound T 0511-1698 was predicted by the pharmacophore model with the correct inhibitory power, demonstrating validity and reliability of the model for certain compounds. Furthermore, compound T 5854015 showed an even lower IC 50 of 9 mM and absent crossinhibition with ASBT and so is the most promising candidate for further studies. Although SOAT and ASBT show high sequence homology, their pharmacophore models significantly differ in their hydrogen bond donor/acceptor groups, which might explain the lack of correlation of the IC 50 values between both carriers for most of the compounds tested. On the other hand, some compounds showed cross-inhibition of SOAT and ASBT, probably because of the overlapped mapping to the three hydrophobic features, which are equally orientated in both pharmacophore models. Therefore, novel SOAT inhibitors should always be tested for cross-inhibition of ASBT and vice versa.
